Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Eiger Biopharmaceuticals, Inc. (CLDN) since 2014 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Eiger Biopharmaceuticals, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1305253.
Total stock buying since 2014: $4,651,451.
Total stock sales since 2014: $9,935,016.
Total stock option exercises since 2014: $1,162,530.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2023 | 352,571 | $152,430 | 4,395 | $4,702 | 0 | $0 |
| 2022 | 100,000 | $128,000 | 37,983 | $111,114 | 0 | $0 |
| 2021 | 2,500 | $21,225 | 3,690 | $40,019 | 0 | $0 |
| 2020 | 50,000 | $393,370 | 0 | $0 | 0 | $0 |
| 2019 | 13,163 | $146,558 | 0 | $0 | 0 | $0 |
| 2018 | 29,000 | $294,587 | 241,265 | $2,895,721 | 4,000 | $8,240 |
| 2017 | 15,000 | $142,950 | 0 | $0 | 0 | $0 |
| 2016 | 212,642 | $3,372,331 | 0 | $0 | 0 | $0 |
| 2015 | 0 | $0 | 291,582 | $5,555,069 | 291,582 | $1,045,562 |
| 2014 | 0 | $0 | 97,079 | $1,328,391 | 97,079 | $108,728 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2023-11 | 123,398 | $34,972 | 0 | $0 | 0 | $0 |
| 2023-10 | 179,173 | $45,858 | 0 | $0 | 0 | $0 |
| 2023-03 | 0 | $0 | 4,395 | $4,702 | 0 | $0 |
| 2023-01 | 50,000 | $71,600 | 0 | $0 | 0 | $0 |
| 2022-12 | 100,000 | $128,000 | 27,500 | $32,407 | 0 | $0 |
| 2022-08 | 0 | $0 | 5,000 | $49,029 | 0 | $0 |
| 2022-03 | 0 | $0 | 3,923 | $21,956 | 0 | $0 |
| 2022-01 | 0 | $0 | 1,560 | $7,722 | 0 | $0 |
| 2021-04 | 2,500 | $21,225 | 0 | $0 | 0 | $0 |
| 2021-03 | 0 | $0 | 2,000 | $20,280 | 0 | $0 |
| 2021-01 | 0 | $0 | 1,690 | $19,739 | 0 | $0 |
| 2020-08 | 10,000 | $114,245 | 0 | $0 | 0 | $0 |
| 2020-03 | 31,000 | $155,760 | 0 | $0 | 0 | $0 |
| 2020-01 | 9,000 | $123,365 | 0 | $0 | 0 | $0 |
| 2019-04 | 12,250 | $135,627 | 0 | $0 | 0 | $0 |
| 2019-02 | 913 | $10,931 | 0 | $0 | 0 | $0 |
| 2018-12 | 10,000 | $106,200 | 0 | $0 | 0 | $0 |
| 2018-11 | 19,000 | $188,387 | 0 | $0 | 0 | $0 |
| 2018-10 | 0 | $0 | 237,265 | $2,855,721 | 0 | $0 |
| 2018-04 | 0 | $0 | 4,000 | $40,000 | 4,000 | $8,240 |
| 2017-09 | 15,000 | $142,950 | 0 | $0 | 0 | $0 |
| 2016-11 | 15,460 | $196,884 | 0 | $0 | 0 | $0 |
| 2016-08 | 192,187 | $3,073,585 | 0 | $0 | 0 | $0 |
| 2016-06 | 3,750 | $77,210 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2023-11-02 | Kayne Richard A | Buy | 23,398 | .30 | 6,972 |
| 2023-11-01 | Kayne Richard A | Buy | 100,000 | .28 | 28,000 |
| 2023-10-31 | Kawas Leen | Buy | 24,332 | .26 | 6,374 |
| 2023-10-31 | Kayne Richard A | Buy | 154,841 | .26 | 39,484 |
| 2023-03-17 | Mayer Eldon C. Iii (Ex VP & Chief Commerc. Officer) | Sale | 4,395 | 1.07 | 4,702 |
| 2023-01-23 | Dietz Thomas John | Buy | 50,000 | 1.43 | 71,600 |
| 2022-12-29 | Murray Christine | Sale | 5,000 | 1.22 | 6,105 |
| 2022-12-22 | Glenn Jeffrey S | Buy | 100,000 | 1.28 | 128,000 |
| 2022-12-22 | Dietz Thomas John | Sale | 22,500 | 1.17 | 26,302 |
| 2022-08-16 | Apelian David | Sale | 5,000 | 9.81 | 49,029 |
| 2022-03-14 | Ryali Sriram (Chief Financial Officer) | Sale | 2,266 | 5.60 | 12,682 |
| 2022-03-14 | Mayer Eldon C. Iii (Ex VP & Chief Commerc. Officer) | Sale | 1,657 | 5.60 | 9,274 |
| 2022-01-07 | Mayer Eldon C. Iii (Ex VP & Chief Commerc. Officer) | Sale | 1,560 | 4.95 | 7,722 |
| 2021-04-09 | Dietz Thomas John (Director) | Buy | 2,500 | 8.49 | 21,225 |
| 2021-03-15 | Loh Evan (Director) | Sale | 2,000 | 10.14 | 20,280 |
| 2021-01-08 | Mayer Eldon C. Iii (Ex VP & Chief Commerc. Officer) | Sale | 1,690 | 11.68 | 19,739 |
| 2020-08-12 | Glenn Jeffrey S (Director) | Buy | 5,000 | 11.36 | 56,780 |
| 2020-08-11 | Glenn Jeffrey S (Director) | Buy | 5,000 | 11.49 | 57,465 |
| 2020-03-16 | Glenn Jeffrey S (Director) | Buy | 30,000 | 5.03 | 150,810 |
| 2020-03-16 | Dietz Thomas John (Director) | Buy | 1,000 | 4.95 | 4,950 |
| 2020-01-24 | Mayer Eldon C. Iii (Ex VP & Chief Commerc. Officer) | Buy | 5,000 | 13.52 | 67,605 |
| 2020-01-10 | Dietz Thomas John (Director) | Buy | 4,000 | 13.94 | 55,760 |
| 2019-04-23 | Dietz Thomas John (Director) | Buy | 5,000 | 11.10 | 55,495 |
| 2019-04-22 | Ryali Sriram (Chief Financial Officer) | Buy | 1,250 | 11.08 | 13,852 |
| 2019-04-22 | Patton Stephana Eilene (See Remarks) | Buy | 1,000 | 11.03 | 11,030 |
| 2019-04-22 | Dietz Thomas John (Director) | Buy | 5,000 | 11.05 | 55,250 |
| 2019-02-04 | Cory David A (President and CEO) | Buy | 570 | 12.70 | 7,069 |
| 2018-12-20 | Dietz Thomas John (Director) | Buy | 5,000 | 9.98 | 49,900 |
| 2018-12-06 | Dietz Thomas John (Director) | Buy | 5,000 | 11.26 | 56,300 |
| 2018-11-29 | Mayer Eldon C. Iii (Director) | Buy | 4,000 | 10.21 | 40,840 |
| 2018-11-27 | Mayer Eldon C. Iii (Director) | Buy | 7,500 | 9.92 | 74,407 |
| 2018-11-26 | Mayer Eldon C. Iii (Director) | Buy | 7,500 | 9.75 | 73,140 |
| 2018-10-18 | Nasr Khaled (10% Owner) | Sale | 237,265 | 12.04 | 2,855,721 |
| 2018-04-02 | Quan Joanne (Chief Medical Officer) | Sale | 4,000 | 10.00 | 40,000 |
| 2018-04-02 | Quan Joanne (Chief Medical Officer) | Option Ex | 4,000 | 2.06 | 8,240 |
| 2017-09-01 | Glenn Jeffrey S (Director) | Buy | 15,000 | 9.53 | 142,950 |
| 2016-11-18 | Glenn Jeffrey S (Director) | Buy | 460 | 12.90 | 5,934 |
| 2016-11-17 | Glenn Jeffrey S (Director) | Buy | 15,000 | 12.73 | 190,950 |
| 2016-08-18 | Cory David A (President and CEO) | Buy | 1,562 | 15.70 | 24,523 |
| 2016-08-18 | Shaffer James P (Chief Business Officer) | Buy | 3,125 | 15.70 | 49,062 |
| 2016-08-18 | Vivo Ventures Vi Affiilates Fund, L.p. (10% Owner) | Buy | 187,500 | 16.00 | 3,000,000 |
| 2016-06-22 | Welch James H (Chief Financial Officer) | Buy | 500 | 19.79 | 9,897 |
| 2016-06-20 | Welch James H (Chief Financial Officer) | Buy | 2,000 | 19.80 | 39,592 |
| 2016-06-13 | Shaffer James P (Chief Business Officer) | Buy | 1,250 | 22.18 | 27,721 |
| 2016-05-23 | Shaffer James P (Chief Business Officer) | Buy | 745 | 19.99 | 14,892 |
| 2016-05-19 | Shaffer James P (Chief Business Officer) | Buy | 500 | 19.52 | 9,760 |
| 2015-04-06 | Zsebo Krisztina M (Chief Executive Officer) | Sale | 47,931 | 18.30 | 877,137 |
| 2015-04-06 | Zsebo Krisztina M (Chief Executive Officer) | Option Ex | 47,931 | 4.56 | 218,565 |
| 2015-04-02 | Laba Rebecque J (VP, Corporate Operations) | Sale | 11,012 | 17.14 | 188,745 |
| 2015-04-02 | Laba Rebecque J (VP, Corporate Operations) | Option Ex | 11,012 | 4.56 | 50,214 |
| 2015-04-01 | Takeya Ryan K (VP, Manufacturing) | Sale | 4,444 | 19.13 | 85,013 |
| 2015-04-01 | Takeya Ryan K (VP, Manufacturing) | Option Ex | 4,444 | 1.12 | 4,977 |
| 2015-03-09 | Zsebo Krisztina M (Chief Executive Officer) | Sale | 47,931 | 24.76 | 1,186,771 |
| 2015-03-09 | Zsebo Krisztina M (Chief Executive Officer) | Option Ex | 47,931 | 4.56 | 218,565 |
| 2015-03-06 | Laba Rebecque J (VP, Corporate Operations) | Sale | 14,000 | 22.89 | 320,390 |
| 2015-03-06 | Laba Rebecque J (VP, Corporate Operations) | Option Ex | 14,000 | 4.56 | 63,839 |
| 2015-03-06 | Honig Peter (Director) | Sale | 5,000 | 25.00 | 125,000 |
| 2015-03-06 | Honig Peter (Director) | Option Ex | 5,000 | 9.58 | 47,900 |
| 2015-03-05 | Honig Peter (Director) | Sale | 4,700 | 22.39 | 105,256 |
| 2015-03-05 | Honig Peter (Director) | Option Ex | 4,700 | 11.30 | 53,110 |
| 2015-03-02 | Takeya Ryan K (VP, Manufacturing) | Sale | 7,777 | 18.48 | 143,718 |
| 2015-03-02 | Takeya Ryan K (VP, Manufacturing) | Option Ex | 7,777 | 1.12 | 8,710 |
| 2015-02-09 | Zsebo Krisztina M (Chief Executive Officer) | Sale | 47,931 | 15.89 | 761,863 |
| 2015-02-09 | Zsebo Krisztina M (Chief Executive Officer) | Option Ex | 47,931 | 4.56 | 218,565 |
| 2015-02-06 | Laba Rebecque J (VP, Corporate Operations) | Sale | 14,000 | 16.08 | 225,119 |
| 2015-02-06 | Laba Rebecque J (VP, Corporate Operations) | Option Ex | 14,000 | 4.56 | 63,839 |
| 2015-02-02 | Takeya Ryan K (VP, Manufacturing) | Sale | 7,777 | 16.35 | 127,153 |
| 2015-02-02 | Takeya Ryan K (VP, Manufacturing) | Option Ex | 7,777 | 1.12 | 8,710 |
| 2015-01-09 | Rudy Jeffrey J (VP, Clinical Operations) | Sale | 10,000 | 18.51 | 185,100 |
| 2015-01-09 | Rudy Jeffrey J (VP, Clinical Operations) | Option Ex | 10,000 | 1.12 | 11,200 |
| 2015-01-07 | Laba Rebecque J (VP, Corporate Operations) | Sale | 20,000 | 17.30 | 346,000 |
| 2015-01-07 | Laba Rebecque J (VP, Corporate Operations) | Option Ex | 20,000 | 1.12 | 22,400 |
| 2015-01-06 | Zsebo Krisztina M (Chief Executive Officer) | Sale | 41,302 | 17.51 | 723,198 |
| 2015-01-06 | Zsebo Krisztina M (Chief Executive Officer) | Option Ex | 41,302 | 1.12 | 46,258 |
| 2015-01-02 | Takeya Ryan K (VP, Manufacturing) | Sale | 7,777 | 19.88 | 154,606 |
| 2015-01-02 | Takeya Ryan K (VP, Manufacturing) | Option Ex | 7,777 | 1.12 | 8,710 |
| 2014-12-09 | Rudy Jeffrey J (VP, Clinical Operations) | Sale | 10,000 | 15.00 | 150,000 |
| 2014-12-09 | Rudy Jeffrey J (VP, Clinical Operations) | Option Ex | 10,000 | 1.12 | 11,200 |
| 2014-12-09 | Zsebo Krisztina M (Chief Executive Officer) | Sale | 41,302 | 15.00 | 619,530 |
| 2014-12-09 | Zsebo Krisztina M (Chief Executive Officer) | Option Ex | 41,302 | 1.12 | 46,258 |
| 2014-12-05 | Laba Rebecque J (VP, Finance and Administration) | Sale | 20,000 | 12.77 | 255,400 |
| 2014-12-05 | Laba Rebecque J (VP, Finance and Administration) | Option Ex | 20,000 | 1.12 | 22,400 |
| 2014-12-01 | Takeya Ryan K (VP, Manufacturing) | Sale | 7,777 | 12.01 | 93,401 |
| 2014-12-01 | Takeya Ryan K (VP, Manufacturing) | Option Ex | 7,777 | 1.12 | 8,710 |
| 2014-11-14 | Rudy Jeffrey J (VP, Clinical Operations) | Sale | 18,000 | 11.67 | 210,060 |
| 2014-11-14 | Rudy Jeffrey J (VP, Clinical Operations) | Option Ex | 18,000 | 1.12 | 20,160 |
Insider trading activities including stock purchases, stock sales, and option exercises of CLDN listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Eiger Biopharmaceuticals, Inc. (symbol CLDN, CIK number 1305253) see the Securities and Exchange Commission (SEC) website.